



August 7, 2025

Consolidated Financial Results for the Three Months Ended June 30, 2025 Terumo Corporation [IFRS]

Company name: TERUMO CORPORATION
 Listing: Tokyo Stock Exchange
 Securities code: 4543
 URL: <https://www.terumo.com/>
 Representative: Hikaru Samejima, Chief Executive Officer
 Inquiries: Jin Hagimoto, Chief Financial Officer, Chief Information Officer
 Telephone: +81-3-6742-8550
 Scheduled date to commence dividend payments: —
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for Securities analysts, Institutional investors)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2025 (from April 1, 2025 to June 30, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year on year changes.)

	Revenue		Operating profit		Profit before tax		Profit for the period		Profit attributable to owners of the parent		Total comprehensive income	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2025	259,965	0.7	55,885	25.2	55,259	21.1	41,843	23.5	41,843	23.5	19,654	(81.7)
June 30, 2024	258,194	19.9	44,640	50.6	45,635	53.1	33,891	50.3	33,891	50.3	107,644	0.4

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2025	28.37	28.36
June 30, 2024	22.82	22.82

(Note) Adjusted operating profit June 2025: 59,103 million yen June 2024: 51,078 million yen

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
June 30, 2025	1,799,436	1,369,071	1,369,071	76.1
March 31, 2025	1,828,393	1,368,535	1,368,535	74.8

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	—	13.00	—	13.00	26.00
Fiscal year ending March 31, 2026	—				
Fiscal year ending March 31, 2026 (Guidance)		15.00	—	15.00	30.00

(Note) Revision from the dividend guidance published most recently: None

3. Consolidated Financial Guidance for the Fiscal Year Ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year on year changes.)

	Revenue		Adjusted operating profit		Operating profit		Profit for the year attributable to owners of the parent		Basic Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	
Full fiscal year	1,050,000	1.3	214,000	5.2	194,000	23.0	143,000	22.2	Yen 96.95

(Note 1) Revision of guidance published most recently: None

(Note 2) Assumed exchange rate: USD1=JPY140, EUR1=JPY160

*Notes

(1) Significant changes in the scope of consolidation during the period: None

Newly included: — (Company Name: —)

Excluded : — (Company Name: —)

(2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies other than (i): None

(iii) Changes in accounting estimates: None

(3) Number of shares outstanding (common stock)

(i) Number of shares outstanding at the end of the period (including treasury shares)

As of June 30, 2025	1,480,559,680 shares	As of March 31, 2025	1,480,559,680 shares
---------------------	----------------------	----------------------	----------------------

(ii) Number of treasury shares at the end of the period

As of June 30, 2025	5,607,807 shares	As of March 31, 2025	5,608,213 shares
---------------------	------------------	----------------------	------------------

(iii) Average number of shares during the period (cumulative from the beginning of the fiscal year)

Three months ended June 30, 2025	1,474,952,053 shares	Three months ended June 30, 2024	1,484,852,049 shares
----------------------------------	----------------------	----------------------------------	----------------------

* Review of Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Explanation on appropriate use of financial guidance and other special notes

1. Forward-looking statements, including financial guidance, contained in these disclosure materials are based on currently available information and assumptions believed to be reasonable by management. This is not a promise or guarantee by the Company that it will achieve these goals. Actual results may differ significantly due to various factors. For the assumptions that are the premise of the financial guidance and the precautions for using the financial guidance, refer to [attached materials], page 6, “1. Overview of Financial Results (4) Future Outlook concerning Consolidated Financial Guidance”.

2. Adjusted operating profit excludes amortization expenses for intangible assets recognized in business combinations and non-recurring profit or loss from operating profit. Adjusted operating profit is the basis for segment profit and is disclosed as it is used as a performance indicator for the Group.

○ Table of contents of attached materials

1. Overview of Financial Results.....	2
(1) Overview of Consolidated Business Results.....	2
(2) Overview of Consolidated Statement of Financial Position.....	5
(3) Cash flow trends.....	5
(4) Future Outlook concerning Consolidated Financial Guidance.....	6
2. Condensed Quarterly Consolidated Financial Statements.....	7
(1) Condensed Quarterly Consolidated Statement of Financial Position.....	7
(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income	9
(3) Condensed Quarterly Consolidated Statement of Changes in Equity	11
(4) Condensed Quarterly Consolidated Statement of Cash Flows	12
(5) Notes to Condensed Quarterly Consolidated Financial Statements	13
(i) Going concern assumption.....	13
(ii) Segment information.....	13

1. Overview of Financial Results**(1) Overview of Consolidated Business Results**

In the three months of the current fiscal year (from April 1 to June 30, 2025), the Group's sales trended strongly amid the expansion of medical demand globally.

Financial results for the first three months are as follows:

(Unit: Millions of yen)

	For the three months ended June 30, 2024	For the three months ended June 30, 2025	Growth (%)	Growth excluding FX impact (%)
Revenue	258,194	259,965	0.7	6.1
Gross profit	137,569	145,467	5.7	8.0
Adjusted operating profit	51,078	59,103	15.7	13.3
Operating profit	44,640	55,885	25.2	21.3
Profit before tax	45,635	55,259	21.1	-
Profit for the period	33,891	41,843	23.5	-
Profit for the period attributable to owners of the parent	33,891	41,843	23.5	-

Revenue by geographic area for the first three months is as follows:

(Unit: Millions of yen)

Geographic area	For the three months ended June 30, 2024	For the three months ended June 30, 2025	Growth (%)	Growth excluding FX impact (%)
Americas	95,939	100,503	4.8	14.5
Europe	54,095	54,299	0.4	2.2
China	23,040	22,935	(0.5)	6.0
Asia and others	32,299	29,419	(8.9)	(1.8)
Overseas total	205,374	207,158	0.9	7.7
Japan	52,819	52,807	(0.0)	(0.0)
Total	258,194	259,965	0.7	6.1

Revenue

Revenue totaled ¥260.0 billion, an increase of 0.7% compared to the same period of the previous fiscal year. Overseas, revenue increased by 0.9% year on year due to expansion in the Terumo Interventional Systems division, centered on access devices, and growth in the plasma innovation business.

In Japan, sales of the Terumo Interventional Systems and the Terumo Neuro divisions were strong, however, sales in the Hospital Care Solutions division decreased, resulting in revenue remaining at the same level compared to the same period of the previous fiscal year.

Profit

Gross profit totaled ¥145.5 billion, an increase of 5.7% compared to the same period of the previous fiscal year, because of the higher revenue.

Adjusted operating profit totaled ¥59.1 billion, an increase of 15.7% compared to the same period of the previous fiscal year, because of the higher gross profit.

Operating profit, profit for the period and profit for the period attributable to owners of the parent respectively increased due to the increase in gross profit.

Adjusted operating profit is a non-IFRS performance indicator. Adjusted operating profit excludes amortization expenses for intangible assets recognized in business combinations and non-recurring profit or loss from operating profit. Adjusted operating profit is the basis for segment profit.

Adjusted operating profit is being used as an indicator by corporate management to monitor earnings performance in each business as a part of the goal to achieve sustainable growth in the mid- to long-term. We believe this is also effective data for users of our financial statements to assess the Group's earnings.

Revenue results of the reportable segments are as follows:

(Unit: Millions of yen)

Segment		For the three months ended June 30, 2024	For the three months ended June 30, 2025	Growth (%)	Growth excluding FX impact (%)
Cardiac and Vascular Company	Revenue	156,714	157,827	0.7	6.8
	(Overseas)	143,688	143,773	0.1	6.7
	(Japan)	13,025	14,054	7.9	7.9
Medical Care Solutions Company	Revenue	51,757	50,402	(2.6)	(1.1)
	(Overseas)	14,664	14,393	(1.8)	3.6
	(Japan)	37,092	36,009	(2.9)	(2.9)
Blood and Cell Technologies Company	Revenue	49,657	51,646	4.0	11.6
	(Overseas)	47,021	48,991	4.2	12.2
	(Japan)	2,636	2,654	0.7	0.7

Cardiac and Vascular Company

Overseas, revenue increased mainly in the Terumo Interventional Systems divisions, however, the impact of foreign exchange rates exerted downward pressure, resulting in revenue remaining at the same level compared to the same period of the previous fiscal year. In Japan, revenue increased by 7.9% year on year, owing to higher sales of the Terumo Interventional Systems and Terumo Neuro divisions. As a result, global revenue increased by 0.7% compared to the same period of the previous fiscal year to ¥157.8 billion.

Medical Care Solutions Company

In Japan, revenue decreased by 2.9% year on year, mainly due to the decline in the Hospital Care Solutions division following the termination of certain business. Overseas, revenue decreased by 1.8% year on year owing to the sales decline in Asia and others. As a result, global revenue decreased by 2.6% compared to the same period of the previous fiscal year to ¥50.4 billion.

Blood and Cell Technologies Company

Global revenue increased by 4.0% compared to the same period of the previous fiscal year to ¥51.6 billion, the Global Blood Solutions performed well thanks to the quicker pace of growth in the plasma innovation business in North America.

(2) Overview of Consolidated Statement of Financial Position

Total assets stood at ¥1,799.4 billion, a decrease of ¥29.0 billion. This was mainly owing to a decrease in goodwill and intangible assets of ¥19.8 billion due to the impact of yen appreciation in foreign exchange rates and a decrease in cash and cash equivalents of ¥17.6 billion due to payments for dividends.

Total liabilities came to ¥430.4 billion, a decrease of ¥29.5 billion. This was mainly attributed to a decrease in other current liabilities of ¥12.0 billion due to the payments of bonuses, a decrease in current tax liabilities of ¥6.4 billion due to the payments of income taxes, a decrease in trade and other payables of ¥5.8 billion due to payments related to equipment and a decrease in bonds and borrowings of ¥5.0 billion resulting from the repayment of long-term borrowings.

Total equity was ¥1,369.1 billion, an increase of ¥0.5 billion. This mainly reflects an increase from profit for the period of ¥41.8 billion, which offset a decrease in other comprehensive income of ¥22.2 billion associated with the yen appreciation in foreign exchange rates and a decrease of ¥19.2 billion from dividends from retained earnings.

(3) Cash flow trends

(Millions of yen)

	For the three months ended June 30, 2024	For the three months ended June 30, 2025	Change
Cash flows from operating activities	35,699	32,639	(3,059)
Cash flows from investing activities	(20,736)	(21,912)	(1,175)
Cash flows from financing activities	(33,223)	(25,830)	7,392
Cash and cash equivalents at the end of the period	194,909	204,294	9,385

Cash flows from operating activities

Net cash provided by operating activities was ¥32.6 billion. The main factors for this were profit before tax of ¥55.3 billion, depreciation and amortization of ¥21.2 billion, income taxes paid of ¥15.2 billion and increase in inventories of 10.5 billion.

Cash flows from investing activities

Net cash used in investing activities was ¥21.9 billion. The main factors for this were a ¥17.0 billion for purchase of property, plant and equipment following capital expenditures for manufacturing facilities and a ¥3.3 billion for purchase of intangible assets following investment in new IT systems.

Cash flows from financing activities

Net cash used in financing activities was ¥25.8 billion. This was mainly due to proceeds from issue of commercial papers of ¥10.0 billion, repayment of long-term borrowings of ¥15.0 billion and payments for dividends of ¥19.0 billion.

In addition to the above, there was a ¥2.5 billion decrease from the effect of exchange rate changes on cash and cash equivalents. As a result, the balance of cash and cash equivalents as of the end of the period stood at ¥204.3 billion, down ¥17.6 billion from the end of the previous fiscal year.

(4) Future Outlook concerning Consolidated Financial Guidance

No changes have been made to the guidance of consolidated financial results announced on May 14, 2025. Although the operating environment is expected to remain uncertain due to changes in the environment surrounding the medical device and pharmaceutical industries and trends in foreign exchange rates and tariff policies in the United States, to achieve its targets the Group will focus on the following: development and sales expansion of high value-added products that contribute to improving the quality and efficiency of medical care, continuous cost improvement, and effective management of selling, general and administrative expenses.

2. Condensed Quarterly Consolidated Financial Statements

(1) Condensed Quarterly Consolidated Statement of Financial Position

	(Unit: Millions of yen)	
	As of March 31, 2025	As of June 30, 2025
Assets		
Current assets		
Cash and cash equivalents	221,872	204,294
Trade and other receivables	176,854	182,010
Other current financial assets	388	117
Inventories	294,385	300,987
Current tax assets	3,218	3,251
Other current assets	26,776	27,418
Total current assets	723,496	718,080
Non-current assets		
Property, plant and equipment	431,078	427,066
Goodwill and intangible assets	545,243	525,409
Investments accounted for using the equity method	1,927	1,589
Other non-current financial assets	40,925	40,190
Deferred tax assets	31,077	31,764
Other non-current assets	54,645	55,336
Total non-current assets	1,104,897	1,081,356
Total assets	1,828,393	1,799,436

	(Unit: Millions of yen)	
	As of March 31, 2025	As of June 30, 2025
Liabilities and Equity		
Liabilities		
Current liabilities		
Trade and other payables	91,029	85,187
Bonds and borrowings	15,000	69,983
Other current financial liabilities	7,834	8,111
Current tax liabilities	23,836	17,400
Provisions	242	228
Other current liabilities	103,022	90,986
Total current liabilities	240,965	271,898
Non-current liabilities		
Bonds and borrowings	159,838	99,872
Other non-current financial liabilities	32,401	30,975
Deferred tax liabilities	5,835	7,216
Retirement benefit liabilities	6,388	6,441
Provisions	617	615
Other non-current liabilities	13,809	13,345
Total non-current liabilities	218,891	158,466
Total liabilities	459,857	430,365
Equity		
Share capital	38,716	38,716
Capital surplus	51,725	51,782
Treasury shares	(14,866)	(14,865)
Retained earnings	1,016,160	1,038,827
Other components of equity	276,800	254,610
Total equity attributable to owners of the parent	1,368,535	1,369,071
Total equity	1,368,535	1,369,071
Total liabilities and equity	1,828,393	1,799,436

(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income

(Condensed Quarterly Consolidated Statement of Profit or Loss)

	(Unit: Millions of yen)	
	For the three months ended June 30, 2024	For the three months ended June 30, 2025
Revenue	258,194	259,965
Cost of sales	120,624	114,498
Gross profit	137,569	145,467
Selling, general and administrative expenses	92,157	91,981
Other income	584	4,133
Other expenses	1,356	1,733
Operating profit	44,640	55,885
Finance income	1,522	873
Finance costs	568	1,278
Share of profit/(loss) of investments accounted for using the equity method	41	(221)
Profit before tax	45,635	55,259
Income tax expenses	11,744	13,415
Profit for the period	33,891	41,843
Attributable to:		
Owners of the parent	33,891	41,843
Total profit for the period	33,891	41,843
Earnings per share		
Basic earnings per share (yen)	22.82	28.37
Diluted earnings per share (yen)	22.82	28.36

(Condensed Quarterly Consolidated Statement of Comprehensive Income)

(Unit: Millions of yen)

	For the three months ended June 30, 2024	For the three months ended June 30, 2025
Profit for the period	33,891	41,843
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Changes in financial assets measured at fair value through other comprehensive income	1,853	(890)
Total items that will not be reclassified to profit or loss	1,853	(890)
Items that are or may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	71,845	(21,298)
Cash flow hedges	(2)	-
Cost of hedging	56	-
Total items that are or may be reclassified subsequently to profit or loss	71,900	(21,298)
Total other comprehensive income for the period	73,753	(22,188)
Total comprehensive income for the period	107,644	19,654
Attributable to:		
Owners of the parent	107,644	19,654
Total comprehensive income for the period	107,644	19,654

(Note) Items in the above statement are net of tax.

(3) Condensed Quarterly Consolidated Statement of Changes in Equity

For the three months ended June 30, 2024

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Total equity
	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity	Total	
Balance as of April 1, 2024	38,716	51,752	(12,436)	954,679	294,379	1,327,090	1,327,090
Profit for the period	-	-	-	33,891	-	33,891	33,891
Other comprehensive income	-	-	-	-	73,753	73,753	73,753
Total comprehensive income	-	-	-	33,891	73,753	107,644	107,644
Acquisition of treasury shares	-	-	(2)	-	-	(2)	(2)
Disposal of treasury shares	-	(81)	188	-	(107)	0	0
Dividends	-	-	-	(16,332)	-	(16,332)	(16,332)
Transfer from retained earnings to capital surplus	-	81	-	(81)	-	-	-
Share-based payments	-	62	(1)	-	-	61	61
Total transactions with owners of the parent	-	62	184	(16,413)	(107)	(16,273)	(16,273)
Balance as of June 30, 2024	38,716	51,815	(12,252)	972,156	368,025	1,418,461	1,418,461

For the three months ended June 30, 2025

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Total equity
	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity	Total	
Balance as of April 1, 2025	38,716	51,725	(14,866)	1,016,160	276,800	1,368,535	1,368,535
Profit for the period	-	-	-	41,843	-	41,843	41,843
Other comprehensive income	-	-	-	-	(22,188)	(22,188)	(22,188)
Total comprehensive income	-	-	-	41,843	(22,188)	19,654	19,654
Acquisition of treasury shares	-	-	(0)	-	-	(0)	(0)
Disposal of treasury shares	-	(2)	2	-	(0)	0	0
Dividends	-	-	-	(19,174)	-	(19,174)	(19,174)
Transfer from retained earnings to capital surplus	-	2	-	(2)	-	-	-
Share-based payments	-	57	(0)	-	-	56	56
Total transactions with owners of the parent	-	57	1	(19,176)	(0)	(19,118)	(19,118)
Balance as of June 30, 2025	38,716	51,782	(14,865)	1,038,827	254,610	1,369,071	1,369,071

(4) Condensed Quarterly Consolidated Statement of Cash Flows

	(Unit: Millions of yen)	
	For the three months ended June 30, 2024	For the three months ended June 30, 2025
Cash flows from operating activities		
Profit before tax	45,635	55,259
Depreciation and amortization	21,003	21,183
Impairment losses	1,266	13
Share of (profit)/loss of investments accounted for using the equity method	(41)	221
Increase/(decrease) in retirement benefit assets or liabilities	412	509
Interest and dividend income	(764)	(851)
Interest expenses	563	475
Foreign exchange (gain)/loss	406	(2,118)
(Gain)/loss on sale and disposal of property, plant and equipment	(40)	65
(Increase)/decrease in trade and other receivables	393	(5,942)
(Increase)/decrease in inventories	1,991	(10,501)
Increase/(decrease) in trade and other payables	(5,154)	(2,453)
Others	(12,187)	(8,113)
Sub-total	53,483	47,749
Interest and dividend income received	998	834
Interest expenses paid	(563)	(723)
Income taxes paid	(18,218)	(15,220)
Net cash provided by operating activities	35,699	32,639
Cash flows from investing activities		
Payments into time deposits	(214)	(126)
Proceeds from withdrawal of time deposits	0	200
Payments for purchase of property, plant and equipment	(15,262)	(16,994)
Proceeds from sale of property, plant and equipment	147	46
Payments for purchase of intangible assets	(3,542)	(3,287)
Proceeds from government grants	-	67
Payments for purchase of financial instruments	(1,765)	(1,750)
Payments for acquisition of shares of subsidiaries, affiliates and other businesses	(100)	(67)
Net cash used in investing activities	(20,736)	(21,912)

(Unit: Millions of yen)

	For the three months ended June 30, 2024	For the three months ended June 30, 2025
Cash flows from financing activities		
Increase/(decrease) in short-term borrowings and commercial papers	20,000	10,000
Proceeds from long-term borrowings	29,969	-
Repayments of long-term borrowings	(160,278)	(15,000)
Proceeds from issue of corporate bonds	69,826	-
Repayments of lease liabilities	(2,004)	(1,845)
Payments for purchase of treasury shares	(2)	(0)
Payments for dividends	(16,153)	(18,984)
Proceeds from settlement of derivatives	25,420	-
Net cash used in financing activities	(33,223)	(25,830)
Effect of exchange rate changes on cash and cash equivalents	8,286	(2,475)
Net increase/(decrease) in cash and cash equivalents	(9,973)	(17,578)
Cash and cash equivalents at the beginning of the period	204,883	221,872
Cash and cash equivalents at the end of the period	194,909	204,294

(5) Notes to Condensed Quarterly Consolidated Financial Statements**(i) Going concern assumption**

Not applicable

(ii) Segment information**(1) General information on reportable segments**

The reportable segments of the Group represent business units which have available discrete financial information and are reviewed regularly at the meeting of the Board of Directors to make decisions about allocation of management resources and assess segment performance.

The Group adopts an in-house company system classified by product groups. The headquarter of each in-house company plans their own comprehensive domestic and international strategies and conducts their own business activities.

Therefore, the Group consists of three reportable segments, Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company, which are organized by the product groups based on the in-house company system.

(2) Reportable segment information

Revenue and operating results of the reporting segments of the Group are described below.

For the three months ended June 30, 2024

	Reportable Segments				Adjustments (Note 1)	(Unit: Millions of yen) Amount recorded on condensed quarterly consolidated financial statements
	Cardiac and Vascular Company	Medical Care Solutions Company	Blood and Cell Technologies Company	Total		
Revenue						
Revenue from sales to external customers	156,714	51,757	49,657	258,128	65	258,194
Segment profit (Adjusted operating profit)	37,157	6,513	6,805	50,476	602	51,078
(Adjustment items)						
Amortization of intangible assets acquired through business combinations	(2,588)	-	(2,867)	(5,456)	(98)	(5,555)
Non-recurring profit or loss (Note 2)						(882)
Operating profit						44,640
Finance income						1,522
Finance costs						(568)
Share of profit/(loss) of investment accounted for using the equity method						41
Profit before tax						45,635

(Note 1) Amounts in “Adjustments” are as follows:

- (1) ¥65 million adjustment to Revenue from sales to external customers is mainly proceeds from outward temporary staffing that is not attributable to reportable segments.
 - (2) ¥602 million adjustment to Segment profit consists of ¥(524) million for preparation expenses to comply with Medical Device Regulation in the EU and ¥1,291 million for inventories.
- (Note 2) ¥(882) million Non-recurring profit or loss mainly includes ¥(1,099) million for business reorganization expenses.

For the three months ended June 30, 2025

	Reportable Segments				Adjustments (Note 1)	(Unit: Millions of yen) Amount recorded on condensed quarterly consolidated financial statements
	Cardiac and Vascular Company	Medical Care Solutions Company	Blood and Cell Technologies Company	Total		
Revenue						
Revenue from sales to external customers	157,827	50,402	51,646	259,876	89	259,965
Segment profit (Adjusted operating profit)	45,678	6,664	7,036	59,378	(274)	59,103
(Adjustment items)						
Amortization of intangible assets acquired through business combinations	(2,366)	-	(2,782)	(5,148)	74	(5,073)
Non-recurring profit or loss (Note 2)						1,855
Operating profit						55,885
Finance income						873
Finance costs						(1,278)
Share of profit/(loss) of investment accounted for using the equity method						(221)
Profit before tax						55,259

(Note 1) Amounts in “Adjustments” are as follows:

- (1) ¥89 million adjustment to Revenue from sales to external customers is mainly proceeds from outward temporary staffing that is not attributable to reportable segments.
- (2) ¥(274) million adjustment to Segment profit consists of ¥(450) million for preparation expenses to comply with Medical Device Regulation in the EU and ¥205 million for inventories.

(Note 2) ¥1,855 million Non-recurring profit or loss includes ¥3,152 million for loss compensation due to the termination of the new contract manufacturing project with a pharmaceutical company and ¥(1,277) million for business reorganization expenses.